Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443526 | 0.99 | KMT2A (0.40) | KMT2ASLC6A3OPRM1HTR2CSLC6A9 | |
| SCHEMBL3992857 | 0.91 | KMT2A (0.43) | KMT2ASLC6A3OPRM1HTR2CSLC6A9 | |
| SCHEMBL3820386 | 0.90 | KMT2A (0.43) | KMT2ASLC6A3OPRM1HTR2CSLC6A9 | |
| SCHEMBL3990504 | 0.90 | KMT2A (0.43) | KMT2ASLC6A3OPRM1HTR2CSLC6A9 | |
| SCHEMBL3819910 | 0.90 | KMT2A (0.43) | KMT2ASLC6A3OPRM1HTR2CSLC6A9 | |
| SCHEMBL3990516 | 0.90 | KMT2A (0.43) | KMT2ASLC6A3OPRM1HTR2CSLC6A9 | |
| SCHEMBL3444024 | 0.89 | SLC6A2 (0.46) | KMT2ASLC6A3OPRM1SLC6A9SLC6A5 | |
| SCHEMBL3444162 | 0.88 | CNR2 (0.45) | KMT2ASLC6A3OPRM1SLC6A9SLC6A2 | |
| SCHEMBL3444664 | 0.88 | OPRM1 (0.53) | KMT2ASLC6A3OPRM1OPRL1SLC6A2 | |
| SCHEMBL3444264 | 0.87 | CNR2 (0.44) | KMT2ASLC6A3OPRM1SLC6A9SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816358-B2 | Pharmaceutical formulations comprising N,N′-disubstituted piperazine compounds | GRUENENTHAL GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-7390812-B2 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2008-06-24 | — | — | US | claimed |
| EP-1496904-B1 | USE OF PHARMACEUTICALS CONTAINING N, N'-DISUBSTITUTED PIPERAZINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-08-15 | — | — | EP | claimed |
| EP-1492781-B1 | N,N'-DISUBSTITUTED PIPERAZINE COMPOUNDS AND THE USE OF THE SAME AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2006-03-08 | — | — | EP | claimed |
| US-20050038034-A1 | Pharmaceutical formulations comprising N,N'-disubstituted piperazine compounds | GRUNENTHAL GMBH (DE) | 2005-02-17 | — | — | US | claimed |
| US-20050026926-A1 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-7816358-B2 | Pharmaceutical formulations comprising N,N′-disubstituted piperazine compounds | GRUENENTHAL GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7390812-B2 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1496904-B1 | USE OF PHARMACEUTICALS CONTAINING N, N'-DISUBSTITUTED PIPERAZINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-08-15 | — | — | EP | disclosed |
| EP-1492781-B1 | N,N'-DISUBSTITUTED PIPERAZINE COMPOUNDS AND THE USE OF THE SAME AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050038034-A1 | Pharmaceutical formulations comprising N,N'-disubstituted piperazine compounds | GRUNENTHAL GMBH (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20050026926-A1 | N, N'-disubstituted piperazine compounds and their use as analgesics | GRUENENTHAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026926-A1 | N, N'-disubstituted piperazine compounds and their use as analgesics | OPRL1, OPRK1, OPRM1 | KMT2A 2869/4885SLC6A3 762/4885OPRM1 3/4885 |
| US-20050038034-A1 | Pharmaceutical formulations comprising N,N'-disubstituted piperazine compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NNT, AANAT | KMT2A 3050/4885SLC6A3 498/4885OPRM1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.